Effects of flow rate on transnasal pulmonary aerosol delivery of bronchodilators via high-flow nasal cannula for patients with COPD and asthma: protocol for a randomised controlled trial.

ABSTRACT:

Introduction

Both in vitro and in vivo radiolabelled studies on nebulisation via high-flow nasal cannula showed that inhaled dose decreases as the administered gas flow increases. In our previous in vitro study, we investigated the effects of the ratio of gas flow to subject's peak inspiratory flow (GF:IF) on the aerosol deposition, which increased as the GF:IF decreased, with an optimal GF:IF between 0.1 and 0.5 producing a stable 'lung' deposition in both quiet and distressed breathing. Thus, we aim to validate our in vitro findings in subjects with reversible airflow limitations by assessing their response to inhaled bronchodilator.

Methods and analysis

This is a single-centre, randomised controlled trial. Subjects with chronic obstructive pulmonary disease or asthma with

SUBMITTER: Li J 

PROVIDER: S-EPMC6597746 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature